Dibucaine
Heavy Solution Nupercaine (dibucaine) is a small molecule pharmaceutical. Dibucaine was first approved as Heavy solution nupercaine on 1982-01-01. It is used to treat irritant dermatitis, pain, pruritus, and sunburn in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dibucaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HEAVY SOLUTION NUPERCAINE | Novartis | N-006203 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dibucaine | OTC monograph final | 2023-05-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| irritant dermatitis | — | D017453 | L24 |
| pain | EFO_0003843 | D010146 | R52 |
| pruritus | HP_0000989 | D011537 | L29 |
| sunburn | EFO_0003958 | D013471 | L55 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AD: Local anesthetics for treatment of hemorrhoids and anal fissures for topical use
— C05AD04: Cinchocaine
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AB: Anesthetics for topical use
— D04AB02: Cinchocaine
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BB: Amide local anesthetics
— N01BB06: Cinchocaine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01H: Local anesthetics, ophthalmologic
— S01HA: Local anesthetics
— S01HA06: Cinchocaine
— S02: Otologicals
— S02D: Other otologicals in atc
— S02DA: Analgesics and anesthetics
— S02DA04: Cinchocaine
HCPCS
No data
Clinical
Clinical Trials
139 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | 1 | 8 | 3 | 18 | 25 | 53 |
| Healthy volunteers/patients | — | 11 | 1 | — | 2 | — | 13 | ||
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 2 | — | 2 | 3 | 7 |
| Thyroid neoplasms | D013964 | EFO_0003841 | 1 | 1 | — | 1 | 3 | 6 | |
| Congenital hypothyroidism | D003409 | E00.1 | — | — | — | 2 | 3 | 5 | |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | 1 | 2 | 2 | — | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 3 | — | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | 1 | 1 | 3 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 1 | — | 2 | — | 3 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | 1 | 1 | 2 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 3 | 4 |
| Hyperthyroxinemia | D006981 | EFO_0004127 | — | — | 2 | — | 1 | 3 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Coronary disease | D003327 | — | — | 1 | — | 1 | 2 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | 1 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 1 | 2 |
| Brain death | D001926 | G93.82 | — | — | 1 | — | 1 | 2 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | 1 | — | 1 | 2 | |
| Dyslipidemias | D050171 | HP_0003119 | — | — | 1 | — | 1 | 2 | |
| Cerebral intraventricular hemorrhage | D000074042 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | 1 | — | — | 2 | 3 |
| Infertility | D007246 | EFO_0000545 | — | 1 | — | — | 1 | 2 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperthyroidism | D006980 | E05.9 | — | — | — | — | 2 | 2 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Pregnancy rate | D018873 | — | — | — | — | 1 | 1 | ||
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
| Food-drug interactions | D018565 | — | — | — | — | 1 | 1 | ||
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | 1 | ||
| Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIBUCAINE |
| INN | cinchocaine |
| Description | Cinchocaine is a monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions. It has a role as a topical anaesthetic. It is a monocarboxylic acid amide, a tertiary amino compound and an aromatic ether. |
| Classification | Small molecule |
| Drug class | local anesthetics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1 |
Identifiers
| PDB | — |
| CAS-ID | 85-79-0 |
| RxCUI | 3339 |
| ChEMBL ID | CHEMBL1086 |
| ChEBI ID | 247956 |
| PubChem CID | 3025 |
| DrugBank | DB00527 |
| UNII ID | L6JW2TJG99 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,415 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more